Business Wire

SMITHS-DETECTION

Share
Smiths Detection launches cutting edge X-ray Diffraction scanner

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has launched the SDX 10060 XDi, a ground-breaking X-ray scanner powered by diffraction technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415145550/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Smiths Detection's ground-breaking SDX 10060 XDi, powered by diffraction technology. (Photo: Business Wire)

X-ray Diffraction (XRD) is a powerful inspection technology offering highly accurate material discrimination and substance identification based on an object’s molecular structure. XRD is particularly suited to detecting constantly evolving compounds in powder, liquid or solid forms, such as ‘homemade’ explosives or narcotics, even for materials with similar densities.

Multi-level baggage and material handling operations and express forwarders are under pressure to screen huge volumes quickly and efficiently. The SDX 10060 XDi can transform this process by automating the resolution of potential explosive alarms, in turn improving both security and efficiency.

Due to its exceptional sensitivity, XRD technology can also be very effectively deployed to support customs agencies in screening for a range of contraband items including narcotics, helping to mitigate ever-growing threats to society.

Jerome de Chassey, President of Smiths Detection, commented: “We are immensely excited to announce the launch of the SDX 10060 XDi which marks a new era in security screening. Every minute of every day our threat detection and security screening technology helps to protect people and infrastructure, and this new development highlights our commitment to making the world a safer place. X-ray Diffraction will future-proof operations for a large variety of sectors, and we are proud to play a pivotal role in shaping the landscape of future threat detection.”

The SDX 10060 XDi can integrate seamlessly with existing material and baggage handling systems and is designed to meet ECAC Standard 3.1/3.2 and TSA 7.2 plus future regulations. Certification is underway.

See how XRD will enhance security here: https://youtu.be/CkoCpsrz97I

Jerome de Chassey, President, Richard Thompson, Vice President Marketing and Strategy, and Matthew Clark, Vice President Technology, will be present at Passenger Terminal Expo 2024 on 16 and 17 April, stand A145 in hall 5.1.

About Smiths Detection:

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 70 years of field-tested experience, Smiths Detection deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals, biological agents, and narcotics – helping make the world a safer place.

For more information visit: http://www.smithsdetection.com/diffraction

About the SDX 10060 XDi:

The Smiths Detection SDX 10060 XDi leverages cutting-edge X-ray Diffraction (XRD) technology to offer unparalleled material discrimination and substance identification capabilities. By generating a unique 'diffraction fingerprint', it can accurately distinguish between substances with similar densities, making it exceptionally effective for identifying homemade explosives and narcotics in various forms. This advanced detection system is especially beneficial for high-volume, high-speed applications such as baggage screening at airports and parcel processing, where it enhances security and operational efficiency.

Discover how the SDX 10060 XDI can elevate your security screening operations here: https://www.smithsdetection.com/products/sdx-10060-xdi/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240415145550/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye